Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Telix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $4.18 billion
P/E Ratio 798.76
Dividend Yield 0.00%
Shares Outstanding 323.99 million
Earnings per share 0.016
Dividend per share N/A
Year To Date Return 27.58%
Earnings Yield 0.13%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Telix Pharmaceuticals Ltd (ASX: TLX)
    Latest News

    A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Do you own today's top performing ASX 200 share?

    Read more »

    Woman looks amazed and shocked as she looks at her laptop.
    Record Highs

    3 ASX 200 stocks rocketing to never-before-seen heights today

    Own these stocks? If so, your investment has never been worth more.

    Read more »

    Share Gainers

    Here are the top 10 ASX 200 shares today

    This tech stock defied its sector's downturn to post a 12% gain today.

    Read more »

    A portrait of Bell Direct market analyst Grady Wulff
    Investing Strategies

    3 shares to buy from the 3 hottest ASX sectors right now

    Bell Potter's Grady Wulff revealed in Sydney the stocks that her team is keen on at the moment.

    Read more »

    A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a good day to be invested in ASX 200 lithium shares.

    Read more »

    top asx shares to buy in summer or to retire represented by piggy bank on sunny beach
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Guess which ASX 200 stock bucked the trend to soar 8% on Wednesday.

    Read more »

    Rich man posing with money bags, gold ingots and dollar bills and sitting on table
    Share Gainers

    3 ASX 300 shares that turned $5,000 into $59,000 or much more in 5 years

    While 10-bagger stocks on the ASX are elusive, they do exist. And they make some investors rich.

    Read more »

    Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
    Healthcare Shares

    Why has the Telix Pharmaceuticals share price rocketed 53% in a month?

    This biopharmaceutical company has been charging ahead lately.

    Read more »

    Top ten gold trophy.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Do you own the ASX 200 lithium share that bested the index on Tuesday?

    Read more »

    Arrows pointing upwards with a man pointing his finger at one.
    Share Gainers

    Why Perenti, Pointsbet, ResMed, and Telix shares are rising today

    These ASX shares are starting the week in a positive fashion.

    Read more »

    A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop
    Mergers & Acquisitions

    Guess which ASX 200 healthcare stock just made a 'powerful' AI acquisition

    The $3.8 million acquisition is expected to complement Telix’s radiopharmaceutical pipeline.

    Read more »

    A woman wearing yellow smiles and drinks coffee while on laptop.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Guess which 'golden' ASX 200 stock posted the index's biggest gain today.

    Read more »

    Frequently Asked Questions

    No, Telix does not pay dividends at this time. 

    Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.

    TLX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Telix Pharmaceuticals Ltd

    Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.

    Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe. 

    The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States. 

    TLX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 Mar 2024 $12.89 $0.03 0.23% 512,920 $12.91 $13.00 $12.80
    27 Mar 2024 $12.86 $0.03 0.23% 903,809 $12.85 $13.04 $12.79
    26 Mar 2024 $12.83 $0.19 1.50% 998,598 $12.68 $12.95 $12.56
    25 Mar 2024 $12.64 $0.05 0.40% 782,938 $12.62 $12.71 $12.36
    22 Mar 2024 $12.59 $-0.68 -5.12% 1,885,422 $13.05 $13.28 $12.39
    21 Mar 2024 $13.27 $0.77 6.16% 2,805,893 $13.50 $13.54 $12.86
    20 Mar 2024 $12.50 $0.35 2.88% 1,364,303 $12.56 $12.86 $12.43
    19 Mar 2024 $12.15 $-0.35 -2.80% 1,115,268 $12.53 $12.81 $12.15
    18 Mar 2024 $12.50 $0.42 3.48% 1,057,745 $12.08 $12.54 $12.01
    15 Mar 2024 $12.08 $0.54 4.68% 7,056,990 $11.52 $12.08 $11.30
    14 Mar 2024 $11.54 $0.34 3.04% 995,518 $11.34 $11.57 $11.27
    13 Mar 2024 $11.20 $-0.03 -0.27% 709,027 $11.35 $11.46 $11.16
    12 Mar 2024 $11.23 $-0.06 -0.53% 594,415 $11.29 $11.42 $11.17
    11 Mar 2024 $11.29 $-0.41 -3.50% 618,417 $11.67 $11.67 $11.29
    08 Mar 2024 $11.70 $0.37 3.27% 1,014,269 $11.46 $11.74 $11.41
    07 Mar 2024 $11.33 $-0.41 -3.49% 784,928 $11.85 $11.85 $11.19
    06 Mar 2024 $11.74 $-0.26 -2.17% 807,388 $11.97 $12.06 $11.65
    05 Mar 2024 $12.00 $0.14 1.18% 1,136,260 $11.57 $12.17 $11.50
    04 Mar 2024 $11.86 $-0.07 -0.59% 966,156 $11.98 $12.20 $11.74
    01 Mar 2024 $11.93 $-0.51 -4.10% 1,356,339 $12.27 $12.44 $11.91
    29 Feb 2024 $12.44 $0.31 2.56% 2,754,966 $11.91 $12.44 $11.82
    28 Feb 2024 $12.13 $0.43 3.68% 1,617,655 $11.79 $12.36 $11.70

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 Jan 2024 Christian Behrenbruch Buy 153,298 $1,686,278
    Exercise of options. Estimated Valuation
    18 Jan 2024 Christian Behrenbruch Cancelled 46,702 $513,722
    Cancellation of securities. 46,702 options were forfeited
    18 Jan 2024 Christian Behrenbruch Exercise 153,298 $1,686,278
    Exercise of options. Estimated Valuation
    30 May 2023 Christian Behrenbruch Issued 120,268 $356,738
    Director remuneration. Black Scholes valuation, 2,59,940 rIGHTS

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Harry Kevin McCann Non-Executive ChairmanNon-Executive Director Sep 2017
    Mr McCann has Board experience with some of Australia's companies. He is a former corporate lawyer and Chairman and Director of listed private and government companies, and government agencies. Mr McCann's expertise in shaping culture (including through organisational and remuneration design), public policy, social performance and stakeholder engagement, enables him to bring insights in these areas. He previously served as Chairman of Macquarie Group and Macquarie Bank Limited (from December 1996 to March 2016), Origin Energy Limited (from January 2000 to October 2013) and the Sydney Harbour Federation Trust (from June 2001 to June 2010 and from June 2015 to June 2018). He was also previously a Director of Bluescope Steel Ltd (from May 2002 to April 2013) and E&P Financial Group Limited (from February 2020 to November 2021). He was also a Director of the U.S. Studies Centre at the University of Sydney (from June 2010 to June 2020) and was a Trustee of the Sydney Opera House (from January 2018 to December 2023). Currently, Mr McCann is a Member of Champions of Change Founding Group (since April 2010), Chairman of Sydney Harbour Foundation Management (since August 2015), Chairman of China Matters (since November 2018), a Director of Haydn Ensemble (since December 2020), and Chair and Board Advisor of Blueprint Institute (since June 2022). Mr McCann practised as a commercial lawyer as a partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. He was made an Officer of the Order of Australia for services to business, corporate governance and gender equality in January 2020. He is member of risk committee and chair of People, Culture and Disclosure Committee.
    Ms Jann E Skinner Non-Executive Director Jun 2018
    Ms Skinner has financial acumen, accounting and auditing expertise, with an understanding of risk management compliance frameworks and control oversight. Her listed company experience and expertise in capital management and corporate development enable her to challenge management constructively. Ms Skinner has experience in auditing, accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. She has served as an independent Non-Executive Director of QBE Insurance Group Limited (since October 2014) and a Director of Create Foundation Limited (since June 2004). She also served as a Director of HSBC Bank Australia Limited (from April 2017 to April 2023). SHe is member of People, Culture Committee and Disclosure Committee and chair of Risk Committee.
    Dr Christian Peter Behrenbruch Chief Executive OfficerManaging Director Jan 2017
    Dr Behrenbruch has radiopharmaceuticals experience and a track record in global healthcare and biotechnology entrepreneurship and technology commercialisation. Dr Behrenbruch has a focus on purpose and values-leadership and is versed in all aspects of running a publicly listed company as both CEO and Director in the U.S. and Australia. Previously, Dr Behrenbruch served as Chief Executive Officer at Mirada Solutions (now Mirada Medical Limited) (from July 2001 to December 2002), President at CTI Molecular Imaging (now Siemens Healthcare) (from August 2003 to September 2006), Chief Executive Officer at Fibron Technologies, Inc. (from June 2008 to December 2011) and Chief Executive Officer at ImaginAb, Inc. (from October 2007 to February 2015). He served as a Director at Siemens Molecular Imaging Ltd (from May 2005 to September 2006), Momentum Biosciences LLC (from July 2007 to June 2009), Radius Health Ltd (now Adaptix Ltd) (from May 2009 to February 2011). Dr Behrenbruch was the Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre) (from October 2012 to July 2014). He is member of Disclosure Committee.
    Dr Andreas Kluge Non-Executive Director Jan 2017
    Dr Kluge's depth of clinical research and development experience in radiochemistry, molecular imaging and clinical development is valued by the Board. He brings a critical mind to the requirements of clinical development of novel radionuclide-based products and devices to enable clinical trials and commercialisation. He is a registered physician and the author of patents and publications in the field of nuclear medicine, neurology, infection and immunology. Dr Kluge is a Founder, General Manager and Medical Director of ABX CRO Advanced Pharmaceutical Services GmbH (since August 2002), a full service Contract Research Organisation (CRO) for Phase I-III biological, radiopharmaceutical and anticancer trials based in Dresden, Germany. He was also a Founder and founding CEO of ABX GmbH (www.abx.de) (from September 1996 to July 2002), one of the manufacturers of radiopharmaceutical precursors globally.
    Dr Mark Alexander Nelson Non-Executive Director Sep 2017
    Dr Nelson has experience in the investment community, including in life sciences. Dr Nelson has served as Chairman of the Caledonia Investments Group (since January 2012) and as a Director of The Caledonia Foundation (since August 2002). He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group (from February 1992 to January 2012). Dr Nelson has served as Chairman of Art Exhibitions Australia (since 2019), Director of the Mindgardens Neuroscience Network (since February 2018), Governor of the Florey Neurosciences Institute (since October 2007), and Director of Kaldor Public Art Projects (since October 2005). He is member of People, Culture and Risk Committee.
    Ms Tiffany Olson Non-Executive Director Mar 2022
    Ms Olson brings experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceuticals sector. Ms Olson's most recent executive role was with Cardinal Health, the largest provider of radiopharmaceuticals in the U.S.. As President of Cardinal Health Nuclear & Precision Health Solutions (from July 2013 to October 2021), overseeing Cardinal's radiopharmaceutical manufacturing and nuclear pharmacy network, she led a business transformation that increased market share and profit growth. Prior to Cardinal Health, Ms Olson served as President of NaviMed (from August 2011 to July 2013), as Vice President Diagnostics at Eli Lilly and Company (from November 2009 to July 2011), and as President and Chief Executive Officer at Roche Diagnostics Corporation (from June 2005 to May 2008). Previously she was a Director at Asuragen, Inc (from August 2016 to March 2021) and at BioTelemetry, Inc. (from February 2019 to February 2021). She currently serves as a Director of Castle Biosciences, Inc. (since April 2021), an Advisory Board member at Langham Logistics (since August 2021), a Director at Education and Research Foundation, Nuclear Medicine & Molecular Imaging (since April 2022) and a Partner at Trusted Health Advisors (since August 2023). She is member of Risk Committee.
    Ms Genevieve Ryan Company Secretary Dec 2022
    -
    Genevieve Ryan Company Secretary
    -
    Richard Valeix Group Chief Commercial Officer
    -
    Darren Smith Group Chief Financial Officer
    -
    Colin Hayward PhD Group Chief Medical Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees ( Limited 38,850,342 11.99%
    J P Morgan Nominees Australia Pty Limited 34,966,849 10.79%
    Citicorp Nominees Pty Limited 29,118,387 8.99%
    Elk River Holdings Pty Ltd As Trustee For The Behrenbruch Family Trust And C Behrenbruch 22,675,000 7.00%
    Gnosis Verwaltungsgesellschaftm B H 22,675,000 7.00%
    National Nominees Limited 11,451,177 3.53%
    Grand Decade Developments Limited 10,947,181 3.38%
    Uv Cap Gmbh & Co Kg 7,454,500 2.30%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 6,623,660 2.04%
    Bnp Paribas Noms Pty Ltd 6,279,603 1.94%
    Bnp Paribas Nominees Pty Ltd i 5,978,960 1.85%
    The Oncidium Foundation 5,929,331 1.83%
    HSBC Custody Nominees (Australia) Limited A/C 2 4,017,015 1.24%
    Lightpoint Medical Ltd 3,298,073 1.02%
    Man Holdings Pty Ltd 3,228,750 1.00%
    Bnp Paribas Nominees Pty Ltd ii 2,922,383 0.90%
    Pacific Custodians Pty Limited 1,990,000 0.61%
    Yelwac Pty Ltd 1,981,804 0.61%
    Netwealth Investments Limited 1,943,357 0.60%
    Ubs Nominees Pty Ltd 1,838,727 0.57%
    Aglub Holdings Pty Ltd 1,733,342 0.54%

    Profile

    since

    Note